How to Overcome the Failure of Alzheimer's Trials

In 2016, an early trial of Addu Canamab showed promise. The drug reduced amyloid plaques and slowed the cognitive decline of Alzheimer's patients. But in 2019, Biogen shut down their Phase 3 clinical trial saying it didn't work. After three decades of global research primarily centered on the amyloid hypothesis, this is the only approved drug that aims at the underlying neurobiology to slow the progression of the disease.